• Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex10-WT1 Ex8 fusion (PubMed=12218078; PubMed=34841430).
  
• Mutation; HGNC; 2348; CREBBP; Simple; p.Arg1443Alafs*11; Zygosity=Unspecified (PubMed=34841430).
  
• Mutation; HGNC; 4172; GATA3; Simple; p.Arg367Ter (c.1099C>T); ClinVar=VCV000016626; Zygosity=Unspecified (PubMed=34841430).
  
• Mutation; HGNC; 9884; RB1; Simple; p.Arg621Ser (c.1861C>A); ClinVar=VCV000135120; Zygosity=Unspecified (PubMed=34841430).
  

PubMed=12218078; DOI=10.1097/01.LAB.0000028059.92642.03
Nishio J., Iwasaki H., Ishiguro M., Ohjimi Y., Fujita C., Yanai F., Nibu K., Mitsudome A., Kaneko Y., Kikuchi M.
Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1.
Lab. Invest. 82:1175-1182(2002)

PubMed=15782132; DOI=10.1038/sj.onc.1208471
Tirado O.M., Mateo-Lozano S., Notario V.
Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax:Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Oncogene 24:3348-3357(2005)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=34413129; DOI=10.1158/1535-7163.MCT-21-0089
Gartrell J., Mellado-Largarde M., Clay M.R., Bahrami A., Sahr N.A., Sykes A., Blankenship K., Hoffmann L., Xie J., Cho H.P., Twarog N., Connelly M., Yan K.-K., Yu J.-Y., Porter S.N., Pruett-Miller S.M., Neale G., Tinkle C.L., Federico S.M., Stewart E.A., Shelat A.A.
SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA-damaging agents.
Mol. Cancer Ther. 20:2151-2165(2021)

PubMed=34841430; DOI=10.1242/dmm.047621
Smith R.S., Odintsov I., Liu Z.-B., Lui A.J.-W., Hayashi T., Vojnic M., Suehara Y., Delasos L., Mattar M.S., Hmeljak J., Ramirez H.A., Shaw M., Bui G., Hartono A.B., Gladstone E., Kunte S., Magnan H., Khodos I., de Stanchina E., La Quaglia M.P., Yao J.-J., Lae M., Lee S.B., Spraggon L., Pratilas C.A., Ladanyi M., Somwar R.
Novel patient-derived models of DSRCT enable validation of ERBB signaling as a potential therapeutic vulnerability.
Dis. Model. Mech. 15:dmm047621.1-dmm047621.15(2022)